CRISPR-Cas-Based Genome Editing for Treating Human Diseases, Part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems have been proven to be a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. Chapters in this release include Current approaches in CRISPR –Cas systems for metabolic disorders, Recent progress in CRISPR –Cas systems for CRISPR for retinal diseases, Recent progress in CRISPR –Cas systems for cataract and blindness, Advances in CRISPR –Cas systems for muscular dystrophy, Recent development in CRISPR –Cas systems for cardiac disease, Current approaches in CRISPR –Cas systems for diabetes, and much more.
Additional sections cover Advances in CRISPR –Cas systems for liver disease, Advances in CRISPR –Cas systems for lung disease, Advances in CRISPR –Cas systems for kidney diseases, Current progress in CRISPR –Cas systems for rare disease, Advances in CRISPR –Cas systems for heredity disease, Recent progress in CRISPR –Cas systems for neurological disorders, and CRISPR challenges in clinical developments.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Contributors - p. xiii 6. Preface - p. xvii 7. Chapter One: Current approaches in CRISPR-Cas system for metabolic disorder - p. 1 8. Chapter Two: Recent progress in CRISPR/Cas9 system for eye disorders - p. 21 9. Chapter Three: Recent development in CRISPR-Cas systems for cardiac disease - p. 47 10. Chapter Four: Current approaches in CRISPR-Cas systems for diabetes - p. 95 11. Chapter Five: Advances in applications of the CRISPR/Cas9 system for respiratory diseases - p. 127 12. Chapter Six: Advances in CRISPR-Cas systems for kidney diseases - p. 149 13. Chapter Seven: Current progress in CRISPR-Cas systems for rare diseases - p. 163 14. Chapter Eight: Current approaches in CRISPR-Cas systems for hereditary diseases - p. 205 15. Chapter Nine: Recent progress in CRISPR-Cas-system for neurological disorders - p. 231 16. Chapter Ten: CRISPR challenges in clinical developments - p. 263 17. Index - p. 281
CRISPR-Cas-Based Genome Editing for Treating Human Diseases, Part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems have been proven to be a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. Chapters in this release include Current approaches in CRISPR –Cas systems for metabolic disorders, Recent progress in CRISPR –Cas systems for CRISPR for retinal diseases, Recent progress in CRISPR –Cas systems for cataract and blindness, Advances in CRISPR –Cas systems for muscular dystrophy, Recent development in CRISPR –Cas systems for cardiac disease, Current approaches in CRISPR –Cas systems for diabetes, and much more.
Additional sections cover Advances in CRISPR –Cas systems for liver disease, Advances in CRISPR –Cas systems for lung disease, Advances in CRISPR –Cas systems for kidney diseases, Current progress in CRISPR –Cas systems for rare disease, Advances in CRISPR –Cas systems for heredity disease, Recent progress in CRISPR –Cas systems for neurological disorders, and CRISPR challenges in clinical developments.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Contributors - p. xiii 6. Preface - p. xvii 7. Chapter One: Current approaches in CRISPR-Cas system for metabolic disorder - p. 1 8. Chapter Two: Recent progress in CRISPR/Cas9 system for eye disorders - p. 21 9. Chapter Three: Recent development in CRISPR-Cas systems for cardiac disease - p. 47 10. Chapter Four: Current approaches in CRISPR-Cas systems for diabetes - p. 95 11. Chapter Five: Advances in applications of the CRISPR/Cas9 system for respiratory diseases - p. 127 12. Chapter Six: Advances in CRISPR-Cas systems for kidney diseases - p. 149 13. Chapter Seven: Current progress in CRISPR-Cas systems for rare diseases - p. 163 14. Chapter Eight: Current approaches in CRISPR-Cas systems for hereditary diseases - p. 205 15. Chapter Nine: Recent progress in CRISPR-Cas-system for neurological disorders - p. 231 16. Chapter Ten: CRISPR challenges in clinical developments - p. 263 17. Index - p. 281
